AudioEye Partners with Ford Medical to Transform Diabetic Eye Care Accessibility
- AEYE Health partners with Ford Medical to enhance diabetic eye exam accessibility in pharmacies and non-acute care centers.
- AEYE-DS is the first FDA-cleared AI solution for portable retinal screening, enabling in-house eye exams with immediate results.
- The initiative aims to improve early detection of diabetic eye disease, enhancing health outcomes and patient access to care.
Revolutionizing Diabetic Eye Care: AEYE Health and Ford Medical Join Forces
AEYE Health, an innovator in AI-powered retinal diagnostics, forges a strategic partnership with Ford Medical, a healthcare distributor dedicated to enhancing support for non-acute care providers. This collaboration aims to address the growing issue of diabetic eye disease by broadening the reach of diabetic eye examinations. With diabetes rates soaring, diabetic retinopathy has emerged as the leading cause of blindness among working-age individuals. Alarmingly, a significant number of diabetic patients do not receive the annual screenings recommended for early detection of this condition. The partnership between AEYE Health and Ford Medical seeks to bridge this care gap by introducing AEYE Health's fully autonomous diabetic eye exam screening solutions to pharmacies and non-acute care centers across the nation.
AEYE Health’s innovative technology, AEYE-DS, stands out as the first FDA-cleared AI solution compatible with a portable camera, facilitating point-of-care screening in settings where access to eye specialists is limited. This development not only makes retinal screening feasible in pharmacies but also empowers these establishments to expand their services. By integrating AEYE-DS into their offerings, pharmacies can conduct in-house, non-invasive eye exams that yield immediate diagnostic results. This capability is particularly significant in non-acute care environments, where patients often face barriers to receiving specialized care. Furthermore, the initiative is fully reimbursable under an existing CPT code, presenting an opportunity for providers to enhance revenue while contributing to the prevention of vision loss.
The partnership's potential extends beyond mere accessibility; it promises to deliver significant clinical value by facilitating early disease detection. Zack Dvey-Aharon, CEO of AEYE Health, expresses enthusiasm for the initiative, highlighting its potential to make diabetic eye exams more accessible to those in need. Scott Greenberg, Vice President of Sales at Ford Medical, echoes this sentiment, pointing out that integrating autonomous AI into everyday care settings can profoundly impact the management of diabetic eye disease. By empowering non-acute care providers with cutting-edge technology, this collaboration aims to improve health outcomes for millions at risk of vision loss, thereby enhancing the overall capability and impact of the healthcare system.
In addition to the partnership, AEYE Health and Ford Medical's initiative underscores a pivotal shift in the delivery of eye care services. As the healthcare landscape evolves, the integration of AI technology into routine care could redefine how patients receive critical screenings, making preventative healthcare more accessible than ever before. This strategic move not only addresses immediate healthcare challenges but also lays the groundwork for a more integrated and patient-centric approach to eye care in the future.
